Podcast: Big Pharma Licensing Trends
Big pharma comprises a smaller proportion of the deals market than mid-size and smaller biopharmas or biotechs, but it is the biggest spender. A free audio/video excerpt on big pharma licensing trends from Datamonitor Healthcare's webinar, "From R&D Investment To Externalization: Where Is The Pharma Industry Maximizing Value?"
Externalization is an important part of big pharma's business model. It is a key growth strategy that complements the investments these companies make in internal research & development. Big pharmas use deal-making to augment their pipelines and portfolios (through in-licensing), and conversely, to monetize non-core assets or to take advantage of unique external capabilities (through out-licensing).
Based on a review of licensing trends from 2012–16, big pharma companies have produced a significant amount of deals across various phases and therapy areas, with a high concentration at the early stages of development, and in oncology.
On May 23, Datamonitor Healthcare presented a webinar "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" Click below for the audio/video deep dive into big pharma licensing trends between 2012 and 2016.
Big Pharma Licensing Trends
For more information about Datamonitor Healthcare, click here.